Abstract A cerebrovascular accident (CVA) may affect basic motor functions, including spasticity that may be present in the upper extremity and/or the lower extremity, post-stroke. Spasticity causes pain, muscle force reduction, and decreases the time to onset of muscle fatigue. Several therapeutic resources have been employed to treat CVA to promote functional recovery. The clinical use of low-level laser therapy (LLLT) for rehabilitation of muscular disorders has provided better muscle responses. Thus, the aim of this study was to evaluate the effect of the application of LLLT in spastic muscles in patients with spasticity post-CVA. A double-blind clinical trial was conducted with 15 volunteer stroke patients who presented with post-stroke spasticity. Both males and females were treated; the average age was 51.5 ± 11.8 years old; the participants entered the study ranging from 11 to 48 months post-stroke onset. The patients participated in three consecutive phases (control, placebo, and real LLLT), in which all tests of isometric endurance of their hemiparetic lower limb were performed. LLLT (diode laser, 100 mW 808 nm, beam spot area 0.0314 cm 2 , 127.39 J/cm 2 /point, 40 s) was applied before isometric endurance. After the real LLLT intervention, we observed significant reduction in the visual analogue scale for pain intensity (p = 0.0038), increased time to onset of muscle fatigue (p = 0.0063), and increased torque peak (p = 0.0076), but no significant change in the root mean square (RMS) value (electric signal in the motor unit during contraction, as obtained with surface electromyography). Our results suggest that the application of LLLT may contribute to increased recruitment of muscle fibers and, hence, to increase the onset time of the spastic muscle fatigue, reducing pain intensity in stroke patients with spasticity, as has been observed in healthy subjects and athletes.
Introduction
Cerebrovascular accident (CVA) is defined as interruption of brain blood supply in a non-traumatic way, impairing demand for oxygen and nutrients, which culminates in tissue injury with impaired neuronal network (focal or global), generating a neurological deficit, with pyramidal release, such as spastic hypertonia [1] [2] [3] .
Spastic hypertonia, or spasticity, leads to metabolic changes in muscle fibers, as well as decreased blood flow and oxidation ability of free fatty acids. Both are responsible for increasing lactic acid production, use of muscle glycogen, pain, and functional limitation characterized as an inability to perform motor tasks [4] [5] [6] .
These metabolic deficits contribute to increased pain after exercise, early onset of muscle fatigue, and weakness. Such factors may lead to difficulty in maintaining an effective and comfortable speed when walking due to high-energy demand and the deficit of aerobic endurance, compromising the functional mobility in chronic stroke patients [5, 7] . Therefore, the fatigued spastic muscles must be among the treatment priorities.
Treatments for neuro-muscular sequelae post-CVA have employed several therapeutic modalities. The implementation of low-level laser therapy (LLLT), for example, has focused on rehabilitation of fatigued muscles, muscular disorders, improved muscle performance in specific muscles treated with LLLT, as well as increased time to onset of muscle fatigue. Thus, LLLT may cause bio-modulators, bio-chemical, bioelectric, and bio-energetic effects [8] .
LLLT can influence the formation of a trans-membrane electrochemical proton gradient in the mitochondria [9] , sodium-potassium pump balance [10] , and repolarization of the neuronal membrane [11] . LLLT can also accelerate cellular metabolic processes and increase synthesis of ATP [8] with an anti-inflammatory effect (release of inflammatory mediators, stimulation of microcirculation, absorption of exudates, and interference in the synthesis of prostaglandins) [12, 13] . Research corroborates the influence of LLLT in relation to the recruitment of muscle fibers and the torque peak, in addition to delaying development of muscle fatigue, which contributes to a greater musculoskeletal performance [6, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] .
We hypothesized that spastic muscles in stroke patients could adapt and reorganize after LLLT, as has been observed in healthy subjects (Fig. 1 ). There is a possibility that LLLT could enhance physical therapy when applied in stroke patients with spastic hemiparesis, improving function. Thus, the purpose of this study was to evaluate the effectiveness of LLLT applied to the rectus femoris muscle and to the vastus medialis muscle where spasticity was present in the lower limb, due to stroke.
Materials and methods
This is an experimental study of cross-sectional analytical character, designed as a double-blind controlled clinical trial. The Research Ethics Committee (CEP) of the Universidade do Vale do Paraiba (UNIVAP) located in São José dos Campos, São Paulo, Brazil, approved this study under CAAE protocol: 1542193.2.00005503 and the Clinical Trials No. NCT02014935. The subjects were recruited from the waiting list of physical therapy clinic at the UNIVAP. We informed all participants about the procedures of the study, and they signed a consent form. The study was performed at the Biodinamic Laboratory of Faculdade de Ciências da Saúde in Universidade do Vale do Paraíba.
Subjects
The study sample consisted of 15 subjects (6 males and 9 females) with a diagnosis of CVA and physical therapy diagnosis of spastic hemiparesis, with a mean age of 51.5 ± 11.8 years; the subjects entered the study ranging from 11 to 48 months post-stroke onset. All the subjects included in the study signed the free and informed consent. We considered the following inclusion and exclusion criteria for sample selection:
Inclusion criteria Patients with spastic hemiparesis, 40-80 years old; who had preserved cognitive system, i.e., ability to respond to verbal stimuli; and who had grade 0 to 2 of spasticity in the extensor muscles of the knee according to the Modified Ashworth Scale. Fig. 1 Flowchart of the muscle tissue alterations caused by spasticity and the LLLT effects in the muscle tissue [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Exclusion criteria Presence of hypoesthesia and/or hyperesthesia of the involved lower limb to be studied; presence of active infection and rash at the site of application of the electrodes to be used for electromyography; joint stiffness, contractures, and deformities; Wernicke and Broca's aphasia; uncontrolled hypertension; presence of neoplastic lesions at the site of application; intake of analgesics and/or anti-inflammatory medications during the 2-week evaluation; stroke patients who were on medication containing steroids or steroid medications; and Fitzpatrick Skin Scale type IV and type V. Normally in a clinic situation, patients with darker-pigmented skin can receive the LLLT treatments, but the laser may need to be moved around on the skin, more frequently due to uncomfortable heating [35] . We wanted to keep the laser application method as consistent as possible across all patients; therefore, those patients with darker-pigmented skin were excluded from this research study. However, in the clinic situation, patients with darker-pigmented skin can routinely receive LLLT.
Procedures
Three physiotherapists (double-blind) performed the subjective evaluation of spasticity through the Modified Ashworth Scale.
We designated three distinct stages with interval of 7 days between them [36] :
& Phase I (control): Individuals not treated with LLLT performed an evaluation that included muscle electrical activity and muscular torque peak of paretic knee extensors during maximum voluntary contraction (MVC), as well as pain intensity before and after MVC; & Phase II (placebo): Individuals treated with LLLT turned off, and evaluation of muscle electrical activity and torque peak of paretic knee extensors during MVC, as well as pain intensity before and after MVC; & Phase III (LLLT): Individuals treated with real LLLT and evaluation of muscle electrical activity and torque peak of paretic knee extensors during MVC, as well as intensity pain before and after MVC.
Phase I (control): First, the pain intensity level at rest was obtained using the visual analogue scale (VAS) for pain, ranging from zero (no pain) to ten (severe pain), for each muscle to be studied. Each participant was asked to point to the level of pain at that moment, on a line representing the VAS pain scale. The point marked by the participant was quantified with the aid of a ruler, where centimeters represented the intensity of pain. Thereafter, we tabulated the observed values on the ruler in a Microsoft Office Excel 2010® spreadsheet.
After applying the VAS, we performed passive warm up on knee extensor muscles of the paretic lower limb with three sets of ten repetitions of flexion-extension of hip and knee joints.
Subsequently, we positioned the participants sitting on the Computerized Isokinetic Dynamometer (Biodex System® 3), where they remained undisturbed for 3 min while we placed the electrodes to obtain the electromyographic signal. We disinfected subjects' skin with 70 % alcohol and placed the surface electrodes Ag/AgCl (circular, 1 cm) 2 cm apart, on the motor point of the rectus femoris and vastus medialis muscles of the paretic lower limb, according to the recommendations of SENIAM (Surface Electromyography for the Non-Invasive Assessment of Muscles). We positioned the reference electrode in the ulna styloid process of the contralateral upper limb. We used the EMG 2 channels of EMG System brand of Brazil Ltda, EMG model 230C. -USB, composed of an A/D (analogue-to-digital converter) 12-bit resolution with 2000 Hz sample rate, unit microvolts, -2000 Xmin, Ymax 2000. The Coef. A 0 and 500 Coef.B were coupled to a computer.
We obtained the electromyographic (EMG) signal of the isometric endurance test from the Computerized Isokinetic Dynamometer. All patients were instructed to perform the MVC of the knee extensor muscles of their paretic lower limb. The subjects performed the MVC for 50 s with the Dynamometer prompt in unilateral isometric mode to knee joint in the pattern of flexion/extension (Away mode). The angle of the lever arm was 60°and anatomical reference was 90°of hip flexion [17] . The subjects performed only one repetition without relaxation time, while the examiner asked for maximum effort through stimulating verbal commands. We applied the VAS once more at the end of isometric endurance test in order to evaluate the intensity of subjects' pain after the MVC exercise of knee extensors, regarding the paretic lower limb.
Phase II (placebo): Seven days later, the subjects returned to the laboratory and we initiated phase II with the application of VAS followed by passive warm up and 3 min of rest. During rest time, we demarcated 30 dots 2 cm away from each other on the patient's skin with a blue marker to locate the 0.25-cm-diameter laser tip immediately lateral to each blue dot for irradiation over the rectus femoris and vastus medialis muscles from the paretic limb (Fig. 2) .
The subjects underwent simulation of LLLT with the equipment (Easy Laser) off. Three minutes later, they underwent isometric contraction endurance test associated with the EMG of rectus femoris and vastus medialis spastic muscles, synchronized to the Dynamometer for muscular torque and fatigue of the paretic limb knee extensors, followed by the application of VAS.
Phase III (LLLT): We followed the same protocol applied in phase II. We started with VAS application, passive warm up, followed by 3 min of resting for the demarcation of irradiation points. However, we performed the application of real LLLT with the parameters described in Table 1 . After the application of LLLT, we positioned the subjects for evaluation of the muscle activity (EMG), torque, fatigue, and pain as described in phase II.
During the application protocol of LLLT, we adopted all safety measures. Everyone present at the site of collection wore safety glasses, suitable to the wavelength used, and we covered the light tip with protective PVC film (Banpack®) to prevent any skin cross-contamination. The PVC film does not cause significant losses in the transmission of low-power laser [37] .
Outcomes and statistical analysis
The processing of the EMG signal and torque peak of the spastic rectus femoris and vastus medialis was conducted through the EMGworks Analysis software, consisting of the Band Pass, four-order Butterworth filter, adjusted for corner frequency 1 (Hz); 2 (Hz) in 20 Hz, and 400 Hz, respectively, aiming to eliminate residual noise. We excluded the first 5 s and the final 5 s of all collected data. The RMS signal values were normalized by MVC neutralizing intra-group differences. We compared the signals obtained in phase I, phase II, and phase III.
Pain levels, obtained by applying the VAS, were expressed as mean and error. We performed statistical analysis of the data in BioEstat® software version 5.3. For descriptive analysis, we used central tendency and standard deviation (SD), with maximum and minimum values. The data referred to phase I passed normality test KS (Kolmogorov-Smirnov), but phase II and phase III were considered not normal. The Wilcoxon statistical test for related samples was used. Alpha was set at a significance level of p = 0.05.
Results
The data of pain intensity are presented in Table 2 , and the time to onset of muscle fatigue, torque peak, and RMS of the rectus femoris and vastus medialis muscles are presented in Table 3 .
The average pain intensity reported by participants in phase I (control) significantly increased after the MVC in phase I (p = 0.0012), phase II (p = 0.0007), and phase III (p = 0.0037), as compared to that observed before the MVC. A significant decrease in pain intensity was found when there was an application of real LLLT before MVC (p = 0.0038), as compared to that observed after MVC in phase I and phase II.
The time to onset of muscle fatigue for the knee paretic extensors was significantly increased when we compared phase I (control) and phase II (placebo), from 25 ± 6.34 to 31.83 ± 9.7 s (p = 0.0020). When we compared phase I (control, 25 ± 6:34 s) with phase III (LLLT, 34.50 ± 3:56 s), we observed a very significant increase (p = 0.0063) at the time to onset of fatigue in the knee extensor muscles post-LLLT. There was no significant difference between phase II (placebo) and phase III (LLLT) (p = 0.2934) ( Table 3) . Regarding the muscular performance (torque peak), there was no significant difference (p = 0.9773) between phases I (control) and II (placebo), with mean values of 39.25 ± 18.16 and 35.01 ± 9.61 N m, respectively. Significant differences (p = 0.0076) were found between phase I (control) and phase III (LLLT), with mean of 46.16 ± 20.17 N m. There was a significant difference (p = 0.0409) between phase II (placebo) and III (LLLT). We can assume from these results ( Table 3 ) that, after application of real LLLT (phase III), there was a significant increase in torque peak of the spastic muscles in the stroke patients.
For the RMS rectus femoris spastic muscle, we found a slight increase (but not significantly so) in signal between the 3 phases, in which phase II (placebo) increased when compared to phase I (control) (p = 0.5701); and phase III (LLLT) increased when compared to phase I (control) (p = 0.6909). This suggests increased recruitment of muscle fibers of the rectus femoris muscle. The vastus medialis muscle showed a slight decrease (but not significantly so) in the signal when recruitment of the muscle fibers between phases were compared. The phase II (placebo) EMG signal decreased compared to the phase I (control) signal (p = 0.6092). The phase III (real LLLT) also decreased compared to phase I (control) (p = 0.9096), indicating a non-significant reduction in the recruitment of the vastus medialis muscle fibers (Table 3) .
Discussion
In the present study, we found that the application of LLLT in spastic muscle, prior to the isometric endurance exercise, contributed to the decrease in pain intensity of patients after completion of the MVC. We believe this is possible due to the ability of LLLT to activate blood reperfusion, with the temporary release of nitric oxide, leading to muscle relaxation and increased peripheral blood microcirculation [15] . Phototherapy is able to promote structural and chemical changes that lead to change in ATP levels and decreased oxidative stress, ensuring greater energy availability for use in cellular activities [8, 16] .
The mechanisms involved in the analgesic effect of LLLT may also be related to muscle relaxation [38] and the stimulated release of endogenous opioids [39] . Phototherapy is able to reduce inflammation [40] and pain intensity [41] as it stimulates the absorption of inflammatory exudates, which favors the absorption of substances like bradykinin, histamine, and acetylcholine [42] . Furthermore, the analgesic effect produced by light may be due, in part, to alterations in structural configuration of the Na/K-ATPase in the membrane-bound Na-K pump resulting in hyperpolarization of the nerve conduction [10, 43] .
Recent clinical trials have shown a reduction of muscle pain intensity in patients after LLLT application [15, 44] . De Moraes Maia et al. [41] showed a statistically significant result (p < 0.001) in pain intensity reduction in 12 patients with myofascial pain, which received application of LLLT in the infrared range (808 nm). Antonialli et al. [45] also found positive results with the application of LLLT pre-MVC exercise, where healthy individuals irradiated with LLLT infrared (905 nm) reported lower pain intensity after exercise.
Regarding the results for onset time of muscle fatigue (Table 3) , we found that the application of LLLT was able to improve both the quality and the duration of the MVC of the subjects. Because spastic muscles have decreased recruitment of motor units with reduced oxidative capacity and endurance [46] , there is depletion of energy reserves, requiring the metabolism of fatty acids to ensure energy reserves. When a muscle is in the spastic state, there is an increased probability of muscle fatigue [46] . Light therapy may promote cellular electrical potential changes and modulate metabolism, thus altering the onset of muscle fatigue [16, 17, 47] . These effects help to explain the results observed in this study.
In the present study, we found a significant increase in torque peak in knee extensors of spastic lower limb when patients received LLLT before MVC (Table 3) . Studies have shown that the use of LLLT results in significant increase in torque peak. According to Lopes-Martins et al. [14] , LLLT (655 nm) led to a significant increase in force peak and reduction of the average time to the fatigue during tetanic contractions in mice, concluding that LLLT can reduce local fatigue and muscle damage after strenuous exercise. Baroni et al. [16] conducted a randomized study in healthy subjects to assess LLLT (810 nm) before the eccentric contraction of knee extensors, through indirect markers of muscle damage. The authors found a significant increase in the percentage of MVC, concluding that the application of LLLT before eccentric exercise is effective in terms of mitigating the increase of muscle proteins in blood serum and increasing strength.
Likewise, Leal Junior et al. [17] conducted a study to evaluate the effects of LLLT (655 nm) on performance and muscle fatigue of the tibialis anterior muscle. They used the isokinetic dynamometer on 14 healthy subjects who underwent a protocol with concentric muscle contraction. The results indicated that when patients were treated with LLLT before exercise, torque peak significantly increased when compared to the previous three measurements without the application of LLLT. The authors concluded that LLLT increases the torque generated by the irradiated muscles, improving musculoskeletal performance, which corroborates the results of our study.
We found that RMS signal of rectus femoris spastic muscle increased after the application of LLLT, which indicates an increase in muscle fiber recruitment during MVC. This suggests that LLLT can influence the response of the myoelectric activity of spastic muscles, promoting the increase in the number of motor units recruited in spastic rectus femoris muscle.
Corroborating the results found in our study, Kelencz et al. [48] with LED phototherapy (640 nm) applied in the masseter muscle found a significant difference in the increase of onset fatigue time (p < 0.001), with no difference in the contraction force and the recruitment of muscle fibers given by the RMS signal. However, a later study, conducted with athletes by Maciel et al. [49] , which applied LLLT (830 nm) in the medial gastrocnemius muscle, showed no significant difference in the increase of the RMS signal (p = 0.1563), the force peak (p = 0.4219), and the onset of muscle fatigue (p = 0.2188). However, Muñoz et al. [29] observed that the masseter muscle activity was significantly higher after LLLT (780 nm) (p < 0.05) compared to control values, even without significant differences in the values of strength and fatigue times (p > 0.05).
Bio-chemical, bio-electric, and bio-energetic phototherapy effects, along with increased mitochondrial function and blood perfusion [8, 50, 51] , support the results found in this study. After application of real LLLT (phase III), the peak strength of the extensor knee muscles of the paretic lower limb increased, which is consistent with increased onset time of muscle fatigue and decreased pain intensity after exercise of MVC. However, we did not find significant changes in the electrical activity of the rectus femoris and vastus medialis spastic muscles. These findings suggest that LLLT may provide better muscle responses in subjects with spastic hemiparesis than has been observed in athletes and healthy individuals. Under these circumstances, further studies that would include a longer application time per point, and a higher number of treatment sessions, would be necessary to confirm and expand on the beneficial effects of LLLT to reduce spasticity post-stroke. Long-term follow-up would also be desirable; it is possible some continued LLLT treatments would be necessary to maintain the initial gains that were made.
Conclusion
Early muscle fatigue and high pain intensity are limiting factors for the functionality of post-stroke patients. Our results suggest that the application of LLLT may contribute to increased recruitment of muscle fibers and, hence, to increased onset time of the spastic muscle fatigue, reducing pain after maximum voluntary contraction. It suggested that the combination of LLLT with conventional motor therapy could promote functional improvement in post-stroke patients with spastic hemiparesis.
